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Abstract
Background: The 23-valent pneumococcal polysaccharide vaccine (PPV23) is recommended for
persons aged < 65 years with chronic medical conditions. We evaluated the risk and mortality from
invasive pneumococcal disease (IPD) among persons with and without the underlying medical
conditions which are considered PPV23 indications.
Methods: Population-based data on all episodes of IPD (positive blood or cerebrospinal fluid
culture) reported by Finnish clinical microbiology laboratories during 1995–2002 were linked to
data in national health care registries and vital statistics to obtain information on the patient's
preceding hospitalisations, co-morbidities, and outcome of illness.
Results: Overall, 4357 first episodes of IPD were identified in all age groups (average annual
incidence, 10.6/100,000). Patients aged 18–49 and 50–64 years accounted for 1282 (29%) and 934
(21%) of IPD cases, of which 372 (29%) and 427 (46%) had a current PPV23 indication, respectively.
Overall, 536 (12%) IPD patients died within one month of first positive culture. Persons aged 18–64
years accounted for 254 (47%) of all deaths (case-fatality proportion, 12%). Of those who died 117
(46%) did not have a vaccine indication. In a survival model, patients with alcohol-related diseases,
non-haematological malignancies, and those aged 50–64 years were most likely to die.
Conclusion: In the general population of non-elderly adults, almost two-thirds of IPD and half of
fatal cases occurred in persons without a recognised PPV23 indication. Policymakers should
consider additional prevention strategies such as lowering the age of universal PPV23 vaccination
and introducing routine childhood pneumococcal conjugate immunisation which could provide
substantial health benefits to this population through indirect vaccine effects.
Background
Streptococcus pneumoniae is a leading cause of serious com-
munity-acquired infections such as bacteraemia and men-
ingitis and community-acquired pneumonia. The
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pneumococcal polysaccharide vaccine (PPV23) is recom-
mended for adults aged 18–64 years with certain chronic
medical conditions and elderly persons because of high
disease rates and increased risk of death [1,2]. Available
information from representative, population-based stud-
ies on the outcome of IPD is limited. Case fatality has gen-
erally been defined as in-hospital mortality, without
extended follow up after discharge from hospital [1,2].
The estimates of PPV23 effectiveness against IPD are high-
est among otherwise healthy young adults [3-6], but
lower among persons with multiple underlying medical
conditions and immunosuppression [7,8]. In the United
States, routine childhood 7-valent pneumococcal conju-
gate vaccine (PCV7) immunisation program has resulted
in dramatic reductions in rates of pneumococcal-related
diseases and major changes in the epidemiology of pneu-
mococcal infections in children and adults because of
reduced transmission of vaccine types and herd protection
in unvaccinated groups [9-11]. In Finland, however, PCV7
has not been introduced in the national immunisation
schedule and the uptake of PPV23 in the recommended
target groups has been extremely low (3%) [12].
We investigated all first episodes of IPD identified by
Finnish microbiology laboratories during 1995–2002 and
linked these national, population-based surveillance data
to other health registries to evaluate the risk and outcome
of IPD among patients with various underlying medical
conditions with special emphasis on the general popula-
tion of working-age adults.
Methods
Surveillance
The Finnish National Health Care System is organised
into 20 geographically and administratively defined
health care districts (HCD), with catchment populations
ranging from 68,000 to 1.4 million (total population 5.2
million). All clinical microbiology laboratories are
required to notify bacterial isolations from blood and cer-
ebrospinal fluid (CSF), including S. pneumoniae, to the
National Infectious Disease Register (NIDR), primarily
through electronic reporting. Each notification includes
information on the date and type of specimen, date of
birth, sex, and place of treatment. Using this information
and a time interval of three months, possible multiple
positive culture results or notifications concerning the
same individual are merged into a single case either by a
notifying laboratory or after the notification is received in
the NIDR database.
Study population and definitions
A case with IPD was defined as isolation of S. pneumoniae
from blood and/or CSF during 1995–2002. Of the total of
4611 IPD episodes identified by the primary diagnostic
laboratory, only the first episode from each case-patient
was included in the analysis (N = 4357); recurrent epi-
sodes and those with missing identification information
were excluded. Pneumococcal bacteraemia was defined as
isolation of S. pneumoniae from blood only and pneumo-
coccal meningitis as isolation of S. pneumoniae from CSF
with or without pneumococcal bacteraemia within 7 days.
Patients with a vaccine indication were defined as those
who had at least one of the underlying medical conditions
for which PPV23 is recommended in Finland (Additional
file 1). This list of conditions is practically identical to that
recommended by the U.S. Advisory Committee on Immu-
nization Practices (ACIP) [13].
Underlying medical conditions
Information on co-morbidities and underlying condi-
tions for IPD patients was obtained by linking the IPD
surveillance database to the following national popula-
tion-based registries using the date of the first positive
specimen for S. pneumoniae and the national identity
code: the Cancer Registry (diagnosis of haematological
and non-haematological malignancy within one year and
five years prior to the specimen date), National Social
Insurance Institution (KELA), National Hospital Dis-
charge Register (HILMO) and NIDR (HIV infection). Pres-
ence of diabetes mellitus, chronic pulmonary disease
(chronic obstructive pulmonary disease [COPD] and
asthma), congenital or acquired immunodeficiency, rheu-
matic or other autoimmune diseases requiring immuno-
suppressive therapy, solid organ or bone marrow
transplantation, cardiac failure, or renal failure were
defined as a KELA record indicating entitlement for reim-
bursement of medications for these conditions. Alcohol-
related diseases (ARD), chronic liver diseases, diseases of
the spleen, and CSF leak were defined as records in
HILMO with one ore more International Classification of
Diseases (ICD), Ninth or 10th  Revision (from 1996
onward) coded discharge diagnoses within one year
before the first positive specimen date (ICD-codes in
Additional file 2).
Vital status (possible date of death) at 7, 28 and 90 days
from the first positive culture of S. pneumoniae for each
case-patient was determined from the National Popula-
tion Information System.
Calculation of incidence rates and statistical analysis
Annual population data from the Statistics Finland during
1995–2002 were used as denominators to calculate age-
and sex-specific incidence rates. In the same way, the
denominators for population at risk in person years for
categories of underlying medical conditions were
obtained from corresponding national health care regis-
tries. Categorical variables were analyzed with the χ2 test
or Fisher's exact test. Continuous variables were analyzedBMC Infectious Diseases 2008, 8:96 http://www.biomedcentral.com/1471-2334/8/96
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by the Mann-Whitney U test. P < .05 was considered to be
statistically significant. Piecewise exponential hazard
regression model [14] was used in age-group 18–64 years
to assess the risk of death with underlying medical condi-
tions for which PPV23 is currently recommended in Fin-
land (Additional file 1), controlling also for other medical
underlying conditions, the type of IPD presentation, age
and sex. Data were analysed by using SPSS for Windows
version 14.0 (Chicago, IL, USA) and Stata 8.2 (College
Station, TX, USA).
Ethical aspects
Use of data collected from population-based registries in
this research was authorised by the Ministry of Social
Affairs and Health, the Finnish Data Protection Authority,
and the National Research and Development Center for
Welfare and Health.
Results
Incidence
During 1995–2002, 4357 first episodes of IPD were iden-
tified in all age groups and 2216 (51%) were persons aged
18–64 years; 1282 (29%) and 934 (21%) were aged
18–49 years and 50–64 years, respectively. The average
annual incidence of IPD was 10.6 cases per 100,000 per-
sons. The median age of cases was 53 years (range, 0–98
years) and 2536 (58%) were males. The median duration
of hospitalisation was 7 days (range, 0–530 days).
Of the cases in all age groups, 4106 (94%) were bacterae-
mias and 251 (6%) meningitis. Within the age group
18–64 years, the rates of bacteraemia and meningitis
increased 2.5 and 3.3 fold with increasing age (Table 1).
The rate of bacteraemia was significantly higher in males
than in females in all age groups; for meningitis the rate
was higher only in males aged 35–49 years.
Underlying conditions
In all age-groups, 2302 (53%) of cases had at least one
underlying condition, including age ≥ 65 years, for which
PPV23 is recommended. However, among working-age
patients aged 18–64 years, only 799 (36%) had a PPV23
indication. Of patients aged 18–49 and 50–64 years 372
(29%) and 427 (46%), respectively, had a condition for
which PPV23 is currently recommended. Among work-
ing-aged persons, alcohol-related diseases, chronic pul-
monary disease and diabetes mellitus were the most
common vaccine indications whereas cardiac failure,
chronic pulmonary disease and diabetes mellitus were
most common among elderly patients (Table 2). Persons
aged 16–84 years accounted for 96% of cases with alco-
hol-related diseases. The highest rates of IPD were seen in
patients with haematological malignancy and organ or
bone marrow transplantation.
Mortality
Of the 4357 cases with IPD, 202 (5%) died on the day of
admission, 373 (9%) died within one week, and 536
(12%) within 28 days. An additional 130 cases died
between 29–90 days after the first blood- and/or CSF-cul-
ture positive for S. pneumoniae (Table 3). Four hundred
and thirty-seven (10%) cases died during the hospitalisa-
tion for IPD. The in-hospital case-fatality proportions
(CFP) within 7, 28 and 90 days were 8%, 10% and 11%,
respectively.
Of all deaths during the first month, persons aged 18–49
and 50–64 years accounted for 124 (23%) and 130
(24%); CFP were 10% and 14%, respectively. The CFP at
7, 28 and 90 days were similar for both sexes in the age
group 18–49 years but significantly higher in men than in
women in persons aged 50–64 years at 28 and 90 days
(17% vs. 9% and 21% vs. 12%; p < 0.01 for both compar-
isons). The CFP at days 28 and 90 were significantly
higher for meningitis than bacteraemia (p < 0.02).
In all age-groups, the highest CFP at 28 days were seen
among persons with non-haematological malignancy,
chronic liver disease, ARD and cardiac failure (Table 2).
Of cases aged 18–64 years, who died on the day of culture
or during the first week, the median ages were 50 and 48
years, respectively, and the most common underlying
medical conditions were ARD, diabetes and immunodefi-
ciency/rheumatic diseases in both groups. Of the fatal
Table 1: Incidence of Streptococcus pneumoniae bacteraemia and meningitis by age and sex, Finland, 1995–2002
Ratea of bacteraemia (no of cases) Ratea of meningitis (no of cases)
Age group (years) Male Female Total Rate ratiob 95% CIc Male Female Total Rate ratiob 95% CIc
0–17 8.3 (386) 6.0 (299) 7.2 (685) 1.4 1.2–1.6 0.5 (22) 0.6 (26) 0.5 (48) 0.8 0.5–1.4
18–34 5.7 (265) 3.2 (142) 4.5 (407) 1.8 1.5–2.2 0.4 (17) 0.1 (6) 0.3 (23) 4.0 0.7–10.1
35–49 11.3 (544) 5.3 (245) 8.4 (789) 2.1 1.8–2.5 0.9 (43) 0.4 (20) 0.7 (63) 2.2 1.3–3.8
50–64 14.6 (546) 8.2 (314) 11.4 (860) 1.8 1.5–2.0 1.1 (42) 0.8 (32) 1.0 (74) 1.4 0.9–2.2
65–74 23.0 (349) 13.9 (275) 17.9 (624) 1.7 1.4–1.9 0.7 (10) 0.9 (17) 0.8 (27) 0.8 0.4–1.7
≥ 75 37.4 (304) 24.1 (437) 28.2 (741) 1.6 1.3–1.8 1.0 (8) 0.4 (8) 0.6 (16) 2.5 0.9–6.7
All 11.9 (2394) 8.1 (1712) 9.9 (4106) 1.5 1.4–1.6 0.7 (142) 0.5 (109) 0.6 (251) 1.4 1.1–1.8
aAverage annual incidence (cases per 100,000 population); bmale to female rate ratio; cCI, confidence intervalBMC Infectious Diseases 2008, 8:96 http://www.biomedcentral.com/1471-2334/8/96
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cases among persons aged 18–49 years and 50–64 years,
61 (49%) and 76 (59%), respectively, had an underlying
condition which is considered a PPV23 indication. The
CFP for patients aged 18–64 years with vaccine indication
was 17% compared with 8% for patients without an indi-
cation (relative risk, 2.1; 95%CI, 1.6–2.6).
Hospital discharge data in connection with the IPD epi-
sode were available for 2132 (96%) of cases aged 18–64
years. We constructed a piecewise exponential hazard
regression model to evaluate the risk of dying associated
with various underlying medical conditions in this group.
In this analysis, 848 (40%) patients had at least one
underlying condition for which PPV23 is recommended
and 1254 (59%) did not have a PPV23 indication. Of all
patients, 477 (22%) had other, non-PPV23 indication dis-
charge diagnosis codes (ICD-9 and ICD-10) given during
the IPD episode or diagnosis codes given during previous
hospitalisations within one year of the episode. The
remaining 807 (38%) cases had neither other diagnoses
nor previous hospitalisations and were considered the
healthy reference group. The underlying medical condi-
tions for which PPV23 is recommended, other diagnoses
for hospitalisations, sex, age (two categories, 18–49 years
and 50–64 years) and type of IPD (bacteraemia or menin-
gitis) were included in the model (Table 4). The highest
hazard ratios (HR) were seen for ARD, HIV infection and
non-haematological malignancy. The HR for male sex, age
50–64 years, meningitis, ARD and haematological malig-
nancy were time-dependent. In ARD the HR was highest
Table 3: Outcome of Streptococcus pneumoniae bacteraemia and meningitis by age and sex, Finland, 1995–2002.
Number of deaths (case fatality proportion, %)
Bacteremia Meningitis
7 days 28 days 90 days 7 days 28 days 90 days
Age group (years) Male Female Male Female Male Female Male Female Male Female Male Female
0–17 2 (0.6) 4 (1.3) 2 (0.6) 4 (1.3) 2 (0.6) 4 (1.3) 1 (4.5) 2 (7.7) 1 (4.5) 2 ( 7 . 7 )1  ( 4 . 5 )2  ( 7 . 7 )
18–34 9 (3.4) 6 (4.2) 15 (5.7) 7 (4.9) 15 (5.7) 8 (5.6) 0 (0.0) 1 (16.7) 2 (11.8) 2 (33.3) 2 (11.8) 2 (33.3)
35–49 43 (7.9) 22 (8.9) 59 (10.9) 27 (11.0) 67 (12.3) 33 (13.5) 4 (9.3) 3 (15.0) 8 (18.6) 4 (20.0) 9 20.9) 5 (25.0)
50–64 53 (9.7) 21 (6.7) 92 (16.7) 28 (8.9) 114 (20.9) 39 (12.4) 4 (9.5) 0 (0.0) 7 (16.7) 3 (9.4) 12 (28.6) 4 (12.5)
65–74 39 (11.2) 26 (9.4) 55 (15.8) 37 (13.4) 76 (21.8) 47 (17.1) 2 (20.0) 4 (23.5) 3 (30.0) 5 (29.4) 3 (30.0) 5 (29.4)
≥ 75 65 (21.4) 58 (13.3) 84 (27.6) 83 (19.0) 100 (32.9) 109 (24.9) 2 (25.0) 2 (25.0) 3 (37.5) 3 (37.5) 3 (37.5) 4 (50.0)
All 211 (8.8) 137 (8.0) 307 (12.8) 186 (10.9) 374 (15.6) 240 (14.0) 13 (9.1) 12 (11.0) 24 (16.9) 19 (17.4) 30 (21.1) 22 (20.2)
Table 2: Risk of invasive Streptococcus pneumoniae infection (IPI) associated with selected underlying conditions, Finland, 1995–2002.
Underlying conditiona Number of IPI cases by age group (years) Population at risk 
(person years)
Rate/100,000/year 95%CIb Case fatality proportion 
at day 7/28/90
< 18 18–64 ≥ 65 All (%)
N = 733 N = 2216 N = 1408 N = 4357
Chronic pulmonary diseasec 44 190 260 494 (11.3) 1,435,000 34.4 31.4–37.4 8/12/15
Cardiac failure 13 51 287 351 (8.1) 746,000 47.1 42.2–52.0 16/24/30
Diabetes mellitus 3 140 186 329 (7.5) 1,014,000 32.5 29.0–36.0 13/19/23
Type 1 diabetesd 3 16 0 19 (0.4) 158,000 12.0 6.6–17.4 5/5/5
Immunodeficiency or rheumatic diseases 4 128 138 270 (6.2) 779,000 34.7 30.5–38.9 14/19/22
Alcohol-related diseases 0 241 10 251 (5.8) 1,117,000e 21.9f 19.1–24.6 21/28/33
Non-haematological malignancy
< 1 year since diagnosis 2 46 58 106 (2.4) 208,000 50.9 41.2–60.6 22/29/41
< 5 years since diagnosis 13 92 139 244 (5.6) 730,000 33.4 29.2–37.6 16/24/33
Haematological malignancy
< 1 year since diagnosis 5 25 26 56 (1.3) 10,000 547.2 398.9–685.5 14/16/25
< 5 years since diagnosis 23 68 72 163 (3.7) 38,000 434.5 367.8–501.2 10/13/21
Organ or bone marrow transplantation 5 26 3 34 (0.8) 21,000 163.7 108.7–218.7 3/6/9
Chronic renal failure 1 15 8 24 (0.6) 27,000 88.6 53.1–124.1 8/13/17
Chronic liver disease 0 15 5 20 (0.5) NAg NA NA 15/30/35
HIV infection 0 10 0 10 (0.2) 8,000 129.7 49.3–210.1 10/20/30
aPatient may have more than one underlying condition; bCI, confidence interval; cchronic obstructive pulmonary disease (COPD) and/or bronchial asthma; ddiabetes mellitus 
diagnosed at age < 30 years and insulin treatment; eextrapolation based on 12 month-prevalence of persons with alcohol use disorders from a representative sample of 
Finland's adult (≥ 30 years) population [21]; fIPI cases with alcohol-related diseases aged ≥ 30 years (N = 245); gNA, not availableBMC Infectious Diseases 2008, 8:96 http://www.biomedcentral.com/1471-2334/8/96
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during the first week, and it was only significant in men-
ingitis from 8 to 28 days and in haematological malig-
nancy from 29 to 90 days. In the model the HR are
multiplicative, e.g. for a male aged 50–64 years with ARD
and meningitis the risk of dying within 28 days was 25
times higher compared to 'previously healthy' group (1.6
× 1.3 × 3.2 × 3.8 = 25.3).
Discussion
Data from our national, population-based study indicate
that about half of all cases and deaths due to IPD occurred
among working-age adults and that only 36% of the cases
in this age-group had any of the underlying conditions for
which PPV23 is currently recommended. To strengthen
the efforts to reduce the high burden of IPD among non-
elderly adults, policymakers should consider new preven-
tion strategies to supplement the current recommenda-
tions for use of PPV23 to reach the almost two-thirds of
cases without a vaccine indication.
By linking surveillance data to national vital statistics we
were able to estimate all-cause mortality up to 3 months
following an episode of IPD. Although the CFP was 9%
during the first week, mortality at one month in persons
with various underlying conditions ranged from 5% to
30% and increased in most groups up to 3 months after
the first positive culture, probably reflecting both the
severity of the underlying illness and the effects of long
term sequelae [15]. The overall mortality was highest for
non-haematological malignancy, chronic liver disease,
alcohol-related diseases, cardiac failure and HIV infection.
Our findings are consistent with two previous population-
based studies on IPD and pneumococcal bacteraemic
pneumonia in which mortality among persons with
underlying medical conditions ranged from 3% to 13%
[2] and 6% to 34% [16], respectively. In both studies the
highest mortality was observed among persons with cir-
rhosis and alcohol abuse, coronary artery disease/conges-
tive heart failure and non-haematological malignancies.
Our survival model for predictors of poor outcome in
non-elderly adults indicated that the conditions with
highest risk of death were alcohol-related diseases and
non-haematological malignancies. The effects of some
patient and disease characteristics such as meningitis as
the clinical syndrome, age 50–64 years, male sex, ARD
and haematological malignancies, seemed time-depend-
ent in predicting death. The hazard ratios for these condi-
tions were either significant only at some time-point in
the model or they changed over time. Of all IPD cases,
about 5% died during the day of admission and ARD was
the most common underlying condition in this group of
patients. The hazard ratios for ARD were higher at 0–7
days than at later time points, possibly reflecting delays in
hospital admissions and treatment in this patient group.
In our study as much as 64% of IPD cases among working-
age adults did not have any of the underlying conditions
for which PPV23 is currently recommended. This propor-
tion is substantially higher than previously reported from
the U.S. (41%) [1,17] but there are few comparable data
available from European countries. Alcohol-related dis-
eases were the most frequent (11%) underlying condition
in the working-age group as they have been in some other
previous studies [18]. The incidence of IPD among per-
sons with ARD in our study, however, was lower (21.9)
compared with estimates ranging from 62 to 483.4 per
100,000 population in previous population-based studies
Table 4: Piecewise exponential hazard regression model for factors associated with death in cases aged 18–64 years with invasive 
pneumococcal infection
Death at 0–7 days Death at 8–28 days Death at 29–90 days
Factor Hazard ratio 95%CIa P-value Hazard ratio 95%CIa P-value Hazard ratio 95%CIa P-value
Male sex 0.9 0.6–1.2 0.5 1.6 1.3–2.0 < 0.001 1.6 1.3–2.0 < 0.001
Age > 50 years 1.3 1.1–1.7 < 0.05 1.3 1.1–1.7 < 0.05 2.8 2.2–3.5 < 0.001
Meningitis 1.2 0.7–2.3 0.7 3.2 2.0–5.0 < 0.001 0.7 0.4–1.2 0.3
Alcohol-related diseases 5.6 3.8–8.1 < 0.001 3.8 2.9–4.9 < 0.001 3.8 2.9–4.9 < 0.001
Cardiac failure 2.6 1.8–3.8 < 0.001 2.6 1.8–3.8 < 0.001 2.6 1.8–3.8 < 0.001
Chronic renal failure 1.6 0.5–5.2 0.4 1.6 0.5–5.2 0.4 1.6 0.5–5.2 0.4
Chronic liver disease 4.4 2.3–8.6 < 0.001 4.4 2.3–8.6 < 0.001 4.4 2.3–8.6 < 0.001
HIV infection 4.8 2.1–10.9 < 0.001 4.8 2.1–10.9 < 0.001 4.8 2.1–10.9 < 0.001
Haematological malignancyb 0.9 0.2–3.5 0.6 0.9 0.2–3.5 0.6 6.9 4.1–11.5 < 0.001
Non-haematological malignancyb 4.7 3.3–6.7 < 0.001 4.7 3.3–6.7 < 0.001 4.7 3.3–6.7 < 0.001
Diabetes mellitus 1.4 0.9–2.0 0.13 1.4 0.9–2.0 0.13 1.4 0.9–2.0 0.13
Chronic pulmonary disease 1.0 0.6–1.6 1.0 1.0 0.6–1.6 1.0 1.0 0.6–1.6 1.0
Organ/bone marrow transplantation 0.9 0.4–1.8 0.7 0.9 0.4–1.8 0.7 0.9 0.4–1.8 0.7
Immunodeficiency/rheumatic diseases 1.7 1.2–2.2 < 0.05 1.7 1.2–2.2 < 0.05 1.7 1.2–2.2 < 0.05
Otherc medical underlying conditions 1.7 1.3–2.2 < 0.001 1.7 1.3–2.2 < 0.001 1.7 1.3–2.2 < 0.001
Healthy Ref.d Ref. Ref.
aCI, confidence interval; b < 1 year since cancer diagnosis; cnon-PPV23 indication; dRef., referenceBMC Infectious Diseases 2008, 8:96 http://www.biomedcentral.com/1471-2334/8/96
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[2,19,20]. However, because of lower base-line incidence
in Finland, difficulties in defining the population at risk
for ARD as well as evaluating the accuracy and represent-
ativeness of the denominator data used in these studies,
the interpretation of the observed differences is complex.
Our estimated denominator for ARD was an extrapolation
based on the 12-month prevalence of persons with alco-
hol use disorders from a representative sample of Finnish
adult (≥ 30 years) population [21].
Among patients with various immunocompromising con-
ditions, the rate of IPD varied from 33.4 to 547.2 per
100,000 and was highest in those with haematological
malignancy. In immunocompetent patients (persons with
diabetes mellitus, chronic pulmonary disease and cardiac
failure) there was less variation in rates (range, 12.0–47.1
per 100,000). Previous population-based studies reported
higher rates for solid cancer (216.1 to 300.4 per 100,000),
chronic pulmonary disease (62.9 to 503 per 100,000) and
HIV (422.9 to 2031.4 per 100,000) [2,19,20], likely
because of differences in population composition, data-
bases, definitions, sources of denominator data and accu-
racy and completeness of identifying diagnoses of
underlying conditions in IPD patients. Previous studies
have included malignancies at any time point [2,20],
whereas we restricted those diagnosed less than five or
one year, respectively, before the IPD episode. For chronic
pulmonary diseases, some studies incorporated only
COPD and emphysema cases [19,20], but we also
included asthma. The relatively low rate of IPD among
persons infected with HIV in Finland may reflect good
access to antiretroviral therapy, early antibiotic treatment
without blood cultures and use of prophylactic antibiotics
among those with low CD4+ T cell count.
Although our estimates from national laboratory-based
surveillance are representative of the entire population of
Finland, the observed IPD incidence was low compared
with reports from some other European countries [22-24],
and the United States [1]. Our previous report from Fin-
land found that the overall average annual incidence of
IPD increased by 35.1% during a 8-year study period and
increased in all adult age groups [25]. In that study tem-
poral increase and higher regional IPD rates were signifi-
cantly associated with higher blood culturing rates
suggesting that the true incidence of IPD may be higher.
Furthermore, although IPD is the most severe manifesta-
tion of pneumococcal infections, it represents only a
small proportion of the overall burden of pneumococcal
disease.
Of the national registries we used to define the co-morbid-
ities for IPD cases and acquire population-based denomi-
nators, the Finnish Cancer Registry has almost 100%
coverage [26,27], and the comprehensiveness of hospital
discharge data has been validated previously [28-31].
However, our study also has several limitations. First, due
to the registry-based study design, our analysis of the clin-
ical outcome lacked chart review data to assess the effect
of severity of illness indicators on IPD-related mortality.
Information on some underlying conditions may also
have been missed. Second, the denominator data for per-
sons with co-morbidities were only available in aggre-
gated form and did not allow estimating age-specific rates
in various groups of patients with co-morbidities. Third, it
is well known that ICD-coding in hospital discharge data
may be incomplete and could be subject to misclassifica-
tion. For this reason, we used hospital discharge data only
to identify underlying conditions (ARD, chronic liver dis-
eases, diseases of the spleen and CSF leakage) for which
data were not available in the two other registries where
standardised criteria and definitions are used. The stand-
ardised reimbursement criteria for underlying conditions
in the National Social Insurance Institution's database
may have excluded mild cases of certain underlying con-
ditions such as COPD and asthma and diabetes mellitus
type 2. Fourth, we did not have information on receipt of
pneumococcal polysaccharide vaccination and cigarette
smoking habits of patients as some of the associations we
found with higher risk of IPD (e.g. alcohol-related dis-
eases and COPD) may be confounded by smoking. About
half of invasive pneumococcal disease in immunocompe-
tent non-elderly adults has been previously attributed to
cigarette smoking [32].
In Finland, the coverage of PPV23 among the elderly and
high risk groups is about 3% and would not be expected
to impact our results. Despite of the existing vaccine rec-
ommendation, PPV23 is not included in the government-
funded national vaccination program, and the expense is
covered by the treating clinical unit or the individual. Two
clinical trials have been conducted in Finland to assess the
efficacy of PPV23 against pneumonia [33,34]. The con-
flicting results from these trials regarding the efficacy in
the aged of PPV23 against mainly serologically diagnosed
pneumococcal pneumonia, or pneumonia in general
probably have also had a major influence on the vaccina-
tion coverage.
The patient groups with highest rates of IPD (e.g. haema-
tological malignancy, organ and bone marrow transplan-
tation, HIV infection) were different from those at highest
risk of death (e.g. ARD, non-haematological malignancy
and cardiac failure). The almost two-thirds of working-age
cases without PPV23 indication, as well as those with
alcohol-related diseases may be difficult to reach with
public health interventions and acceptability of vaccina-
tion may be low among healthy persons. One proposed
strategy includes lowering the recommended age for uni-
versal PPV23 vaccination to include all persons aged 50BMC Infectious Diseases 2008, 8:96 http://www.biomedcentral.com/1471-2334/8/96
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years and older which might result in moderately
increased number of IPD cases prevented compared with
the current high risk indications [35,36]. However, given
the increasing risk of IPD and mortality with age and the
unknown duration of protection after primary immunisa-
tion, the optimal timing and frequency of revaccination
with PPV23 will need to be determined before this strat-
egy can be implemented. Currently, there are no data
available on the clinical effectiveness of revaccination and
serologic studies suggest that antibody responses may by
lower after revaccination that after primary vaccination
[37-39].
Routine childhood immunisation with PCV7 has not yet
been introduced in Finland. However, increasing evidence
has been accumulating about the substantial indirect
effects of childhood PCV7 immunisation in reducing rates
of adult pneumococcal disease in the U.S. and elsewhere
[40,41], although early reports from some European
countries have had inconsistent results [42-45]. The sero-
types included in PCV7 cause approximately 50% of IPD
in Finnish adults, a proportion similar to the U.S. before
PCV7 introduction [25]. Therefore, introducing routine
childhood immunisation in Finland would provide an
opportunity to substantially reduce the disease burden
among the difficult-to-reach groups of working-age adults
without PPV23 indications [11].
Conclusion
In addition to young children and elderly persons, the
burden of invasive pneumococcal infections is also sub-
stantial among working-age persons without high risk
conditions. In the general population of non-elderly
adults, two-thirds of invasive infections and one half of
fatal cases occur in persons without a recognised PPV23
indication. Policymakers should therefore consider addi-
tional prevention strategies to reduce the burden of pneu-
mococcal disease in the overall population.
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